Related Experiment Video
Updated: Dec 11, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
P-selectin (CD62P) and soluble TREM-like transcript-1 (sTLT-1) are associated with coronary artery disease: a case
Li Shen1, Tianlun Yang2, Ke Xia2
1Department of Cardiology, The Third Hospital of Changsha, Changsha, Hunan, China.
Insights
Soluble TREM-like transcript-1 (sTLT-1) and Platelet P-selectin (CD62P) are elevated in coronary artery disease (CAD) patients. These markers, particularly sTLT-1, show potential as new indicators for platelet activation in CAD.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Biomarker Discovery
Background:
- Platelet activation is integral to the development of coronary artery disease (CAD).
- Platelet P-selectin (CD62P) is a known indicator of platelet activation.
- Soluble TREM-like transcript-1 (sTLT-1) is an emerging biomarker for platelet activation.
Purpose of the Study:
- To investigate platelet P-selectin (CD62P) expression and serum soluble TREM-like transcript-1 (sTLT-1) levels in patients with CAD.
- To assess the relationship between CD62P, sTLT-1, and CAD, particularly in acute coronary syndrome (ACS).
Main Methods:
- Measured CD62P and sTLT-1 levels in 83 CAD patients and 49 controls.
- Examined associations between these markers and clinical factors like age, blood pressure, and lipid profile.
Main Results:
- CD62P levels were significantly higher in CAD patients compared to controls (P < 0.01).
- sTLT-1 levels were elevated in patients with acute myocardial infarction (AMI) and unstable angina pectoris (UAP) compared to normal controls (P < 0.01).
Conclusions:
- Elevated sTLT-1 and CD62P levels in CAD patients suggest their role in platelet activation.
- sTLT-1 may serve as a novel, valuable biomarker for platelet activation and CAD.
Background:
Platelet activation plays a crucial role in the pathogenesis of coronary artery disease (CAD). Platelet P-selectin (CD62P) is a classic platelet activation indicator on the platelet surface, and soluble TREM-like transcript-1 (sTLT-1) is a new indicator. However, the relationship between these two markers and CAD, especially in acute coronary syndrome (ACS), has not been elucidated. This study aimed to investigate CD62P expression on the platelet surface and sTLT-1 expression in serum, as well as to assess their relationship with CAD.
Methods:
We measured the levels of CD62P and sTLT-1 in 83 patients with CAD compared to 49 controls. The association of these indicators with age, blood pressure, lipid profile, body mass index, and liver injury marker level were also examined.
Results:
CD62P concentration was higher in CAD patients than in the control group (P < 0.01), especially in acute myocardial infarction (AMI) patients (P < 0.01). Serum sTLT-1 concentration was higher in the AMI and unstable angina pectoris (UAP) groups than in the normal control (NC) group (P < 0.01).
Conclusions:
The consistency of sTLT-1 and CD62P expression levels in CAD patients indicates that sTLT-1 level, the same as CD62P, may be a new marker of platelet activation that is positively related to CAD.
More Related Videos
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
08:13Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
Published on: December 3, 2020
Related Concept Videos
01:25Selectins
01:26Coronary Artery Disease II: Pathophysiology
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Coronary Artery Disease I: Introduction